TM Owner AstraZeneca
Truqap 200mg Tablet
Global Shipping : Reliable Global Distribution Network
Express Delivery : Priority Shipping for Every Order
Secure Payments : Trusted Payment Protection System
Disclaimer
Secure Handling
24/7 Worldwide Support
Global Access
Worldwide Access to Health
Cold-Chain Expert
Excellence in Cold-Chain
Trusted Supply
Certified Medical Supply
Indications & Clinical Uses
- Truqap 200 mg tablets contain capivasertib, an AKT kinase inhibitor taken by mouth, dosed as 400 mg (two 200 mg tablets) twice daily for 4 days followed by 3 days off, repeated weekly.
- Truqap was first approved by the FDA in November 2023, in combination with fulvestrant, for adults with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer whose tumor carries one or more PIK3CA, AKT1 or PTEN alterations detected by an FDA-approved test, following progression on endocrine-based therapy.
- In June 2026 the FDA additionally approved Truqap, combined with abiraterone and prednisone, for PTEN-deficient metastatic hormone-sensitive (androgen pathway modulation-naive or -sensitive) prostate cancer, so Truqap is no longer a women's-cancer-only medicine; it is manufactured by AstraZeneca.
Side Effects
- Truqap has no boxed warning on its current US label.
- In the breast cancer combination, very common effects (affecting more than half of patients) include diarrhea, skin reactions (rash), high blood glucose, low lymphocyte counts and tiredness; similar effects, plus low hemoglobin, occur with the prostate cancer combination.
- Diarrhea and skin rash are usually the earliest signs of a reaction needing dose adjustment.
- Report urgently: severe or persistent diarrhea with dehydration, blistering or widespread rash (possible severe skin reaction such as Stevens-Johnson syndrome or DRESS), and symptoms of very high blood sugar such as excessive thirst, frequent urination, confusion or fruity-smelling breath, which can progress to diabetic ketoacidosis.
Precautions & Warnings
- Blood glucose should be checked before starting Truqap and monitored regularly during treatment, especially in people with diabetes or risk factors for hyperglycemia; severe hyperglycemia and diabetic ketoacidosis, including fatal cases, have occurred.
- Skin should be monitored for rash, and Truqap should be interrupted, reduced or stopped for severe reactions; treatment is stopped permanently for confirmed Stevens-Johnson syndrome, toxic epidermal necrolysis or DRESS.
- Diarrhea should be managed promptly with antidiarrheal medicine and fluids.
- Truqap can cause fetal harm, so effective contraception is required during treatment and for a period after the last dose in both patients and partners; it should not be used in pregnancy.
- Store tablets at 20°C to 25°C (68°F to 77°F), excursions to 15°C to 30°C permitted, in the original bottle.
Avoid Interactions
- Tell your healthcare provider about all medicines, herbal products and supplements you take before starting Truqap.
- Avoid strong CYP3A4 inhibitors (such as ketoconazole, itraconazole, clarithromycin, and grapefruit or grapefruit juice), which raise capivasertib levels and toxicity; if a moderate CYP3A4 inhibitor cannot be avoided, the Truqap dose is usually reduced.
- Avoid strong and moderate CYP3A4 inducers (such as rifampin, carbamazepine, phenytoin and St John's Wort), which can reduce Truqap's effectiveness.
- Because Truqap is combined with fulvestrant or with abiraterone and prednisone, all of the interaction precautions and monitoring requirements for those medicines also apply, so report every medicine you use.
References
Frequently Asked Questions
Truqap (capivasertib) treats HR-positive, HER2-negative advanced breast cancer with a PIK3CA, AKT1 or PTEN gene change, combined with fulvestrant. Since June 2026 it is also approved with abiraterone and prednisone for PTEN-deficient advanced prostate cancer, so it treats both breast and prostate cancer.
Truqap is taken as two 200 mg tablets (400 mg) by mouth twice daily, about 12 hours apart, with or without food. You take it for 4 days, then stop for 3 days, and repeat this weekly cycle alongside fulvestrant or abiraterone and prednisone.
The most common Truqap side effects are diarrhea, skin rash, high blood sugar, low lymphocyte counts and fatigue. Truqap has no boxed warning. Get urgent help for severe rash, severe diarrhea, or signs of very high blood sugar like extreme thirst or confusion.
Avoid grapefruit and strong CYP3A4 inhibitors like ketoconazole and clarithromycin, which raise Truqap levels. Avoid strong inducers such as rifampin and St John's Wort, which weaken its effect. Effective contraception is required, as capivasertib can harm an unborn baby.
Yes. Truqap can cause high blood sugar and, rarely, diabetic ketoacidosis, so blood glucose is checked before starting and monitored regularly during treatment. Tell your healthcare provider if you have diabetes, and report excessive thirst, frequent urination or confusion right away.
No, not anymore. Truqap was first approved for HR-positive, HER2-negative breast cancer in women, but in June 2026 the FDA also approved it, with abiraterone and prednisone, for PTEN-deficient metastatic hormone-sensitive prostate cancer in men.
Trusted & Reliable – Your Partner in Global Distribution.
We provide comprehensive lines of pharmaceutical products to support all your healthcare distribution needs.
